Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomi
2 hours ago
- #DLBCL
- #phase 2 trial
- #first-line therapy
- Study evaluated epcoritamab monotherapy vs. epcoritamab with lenalidomide as first-line therapy for older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) ineligible for anthracycline-based chemoimmunotherapy.
- In stage 1, complete response rate was 63.6% with monotherapy vs. 45.5% with combination therapy; common grade ≥3 adverse events included infections (18%) and fatigue (14%) for monotherapy, and neutropenia (40%) and infections (38%) for combination.
- Based on efficacy and safety, epcoritamab monotherapy was selected for expansion in stage 2; overall complete response rate across stages was 57.6%, with manageable safety profile, supporting further investigation as a chemotherapy-free option.